Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Gingival mesenchymal stem cell-derived exosomal miR-23a-3p targets IL-6R to attenuate autoimmune insulitis: a cell-free therapeutic strategy for type 1 diabetes

Qu Q., Liu SY., Fu B., Ao Q., Long Y., Liu ZY.

Animal Study on Type 1 Diabetes, Immune Modulation, Autoimmune Research, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Stem Cell Res Ther (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41225616
PMCID
PMC12613438
DOI
10.1186/s13287-025-04744-1
Citations
2

Abstract (original English)

Background Type 1 diabetes (T1D) is characterized by autoimmune destruction of pancreatic β-cells, yet current therapies fail to address immune dysregulation. Gingival mesenchymal stem cells (GMSC) exhibit immunomodulatory potential, but cell-based therapies face challenges in standardization and survival. Exosomes, nanosized vesicles delivering bioactive molecules like miRNAs, offer a cell-free alternative. This study investigates GMSC-derived EXO (GMSC-EXO) enriched with miR-23a-3p as a novel strategy to attenuate T1D progression. Methods Spontaneous T1D in NOD/LtJ mice was treated with GMSC-EXO. Exosome secretion was inhibited using GW4869, and miR-23a-3p was knocked down via LV3-miR-23a-3p inhibitor. Blood glucose, pancreatic inflammation, and immune cell dynamics were monitored in vivo. CD4 + T-cell subsets (Th1/Th17, Tregs) and cytokine levels were analyzed via flow cytometry and ELISA. Dual-luciferase assays and Western blot validated miR-23a-3p targeting of IL-6R and downstream IL-6R/JAK1/STAT3 signaling. Results GMSC-EXO delayed hyperglycemia progression and improved survival. Depleting exosomes or miR-23a-3p diminished therapeutic efficacy. Mechanistically, miR-23a-3p directly silenced IL-6R, suppressing IL-6R/JAK1/STAT3 signaling, reducing Th1/Th17 infiltration, and expanding Tregs and IL-10 + cells. In vitro, GMSC-EXO reduced IFN-γ/IL-17 A and elevated IL-10, effect

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Mesenchymal Stem CellsGingivaAnimalsMice, Inbred NODHumansMiceDiabetes Mellitus, Type 1Receptors, Interleukin-6MicroRNAsFemale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research